Standard BioTools Q2 revenue falls on consumables weakness - LAB News | RalliesStandard BioTools Q2 revenue falls on consumables weakness
L
LAB• Outlook
- Company is withdrawing its full-year 2026 revenue outlook due to pending merger with Treeline Biosciences
- Standard BioTools expects to close the Treeline Biosciences merger before year-end 2026
Overview
- U.S. life science tools firm's Q2 revenue fell 8% yr/yr amid weaker consumables demand
- Adjusted EBITDA loss for Q2 narrowed 84% yr/yr, reflecting cost discipline and restructuring
- Company is progressing toward the Treeline Biosciences merger; full-year revenue outlook withdrawn
Key details
| Metric | Actual |
|---|
| Q2 Revenue | $20.10 mln |
| Q2 Loss Per Share | $0.07 |
| Q2 Net Loss | $26.76 mln |
| Q2 Adjusted EBITDA | -$2.50 mln |
| Q2 Gross Margin | 52.40% |
| Q2 Adjusted Gross Margin | 56.30% |
| Q2 Operating Income | -$25.40 mln |
| Q2 Pretax Loss | -$21.44 mln |
Result drivers
- Consumables weakness - Co said consumables revenue declined 10% yr/yr due to strong prior year and continued U.S. academia spend uncertainty
